nach oben

Erschienen in:

17.06.2019 | Review articles

Prevalence of TTN mutations in patients with dilated cardiomyopathy

A meta-analysis

verfasst von: H.-J. Fang, MM, B.-P. Liu, MPH

Erschienen in: Herz | Sonderheft 1/2020

Einloggen, um Zugang zu erhalten

Abstract

A meta-analysis was performed to assess the prevalence of TTN mutations in patients with dilated cardiomyopathy (DCM). Prevalence point estimates and 95% confidence intervals were computed using the logit transformation formula. The prevalence of TTN mutations in patient with DCM, familial dilated cardiomyopathy (FDCM), and sporadic dilated cardiomyopathy (SDCM) was 0.17 (95% CI: 0.14–0.19), 0.23 (95% CI: 0.20–0.26), and 0.16 (95% CI: 0.12–0.21), respectively. No individual study had a marked influence on the pooled prevalence in the meta-analysis. Meta-regression analysis between the logit event for prevalence and sample size explained 32% of between-study variance (p < 0.05). Cumulative meta-analysis confirmed the influence of sample size on the reported prevalence among the different studies. In conclusion, the present analysis suggests that TTN mutations are familial in DCM patients. More attention should be paid to TTN mutations in clinical examinations.

Nur mit Berechtigung zugänglich

Richardson P, McKenna W, Bristow M et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93(5):841–842CrossRef

Menon SC, Olson TM, Michels VV (2008) Genetics of familial dilated cardiomyopathy. Prog Pediatr Cardiol 25(1):57–67. https://doi.org/10.1016/j.ppedcard.2007.11.013CrossRef

Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29(2):270–276. https://doi.org/10.1093/eurheartj/ehm342CrossRefPubMed

Jefferies JL, Towbin JA (2010) Dilated cardiomyopathy. Lancet 375(9716):752–762. https://doi.org/10.1016/S0140-6736(09)62023-7CrossRefPubMed

Garcia-Pavia P, Cobo-Marcos M, Guzzo-Merello G et al (2013) Genetics in dilated cardiomyopathy. Biomark Med 7(4):517–533. https://doi.org/10.2217/bmm.13.77CrossRefPubMed

Cho KW, Lee J, Kim Y (2016) Genetic variations leading to familial dilated cardiomyopathy. Mol Cells 39(10):722–727. https://doi.org/10.14348/molcells.2016.0061CrossRefPubMedPubMedCentral

Garfinkel AC, Seidman JG, Seidman CE (2018) Genetic pathogenesis of hypertrophic and dilated cardiomyopathy. Heart Fail Clin 14(2):139–146. https://doi.org/10.1016/j.hfc.2017.12.004CrossRefPubMedPubMedCentral

Kayvanpour E, Sedaghat-Hamedani F, Amr A et al (2017) Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol 106(2):127–139. https://doi.org/10.1007/s00392-016-1033-6CrossRefPubMed

Petretta M, Pirozzi F, Sasso L, Paglia A, Bonaduce D (2011) Review and metaanalysis of the frequency of familial dilated cardiomyopathy. Am J Cardiol 108(8):1171–1176. https://doi.org/10.1016/j.amjcard.2011.06.022CrossRefPubMed

10.

Akinrinade O, Koskenvuo JW, Alastalo T‑P (2015) Prevalence of Titin truncating variants in general population. PLoS ONE. https://doi.org/10.1371/journal.pone.0145284CrossRefPubMedPubMedCentral

11.

Fatkin D, Huttner IG (2017) Titin-truncating mutations in dilated cardiomyopathy: the long and short of it. Curr Opin Cardiol. https://doi.org/10.1097/hco.0000000000000382CrossRefPubMed

12.

Herman DS, Lam L, Taylor MR et al (2012) Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366(7):619–628. https://doi.org/10.1056/NEJMoa1110186CrossRefPubMedPubMedCentral

13.

Guo W, Bharmal SJ, Esbona K, Greaser ML (2010) Titin diversity-alternative splicing gone wild. J Biomed Biotechnol. https://doi.org/10.1155/2010/753675CrossRefPubMedPubMedCentral

14.

Fatkin D, Lam L, Herman DS et al (2016) Titin truncating mutations: a rare cause of dilated cardiomyopathy in the young. Prog Pediatr Cardiol 40:41–45. https://doi.org/10.1016/j.ppedcard.2016.01.003CrossRef

15.

Hershberger RE, Siegfried JD (2011) Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 57(16):1641–1649. https://doi.org/10.1016/j.jacc.2011.01.015CrossRefPubMedPubMedCentral

16.

Haas J, Frese KS, Peil B et al (2015) Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 36(18):1123–U1143. https://doi.org/10.1093/eurheartj/ehu301CrossRefPubMed

17.

Alaa Rostom, Catherine Dubé, Ann Cranney et al. Celiac Disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Sep. (Evidence Reports/Technology Assessments, No. 104.) Appendix D. Quality Assessment Forms. https://www.ncbi.nlm.nih.gov/books/NBK35149/.

18.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634CrossRef

19.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRef

20.

Franaszczyk M, Chmielewski P, Truszkowska G et al (2017) Titin truncating variants in dilated cardiomyopathy—prevalence and genotype-phenotype correlations. PLoS ONE 12(1):e169007. https://doi.org/10.1371/journal.pone.0169007CrossRefPubMedPubMedCentral

21.

Akinrinade O, Ollila L, Vattulainen S et al (2015) Genetics and genotype-phenotype correlations in Finnish patients with dilated cardiomyopathy. Eur Heart J 36(34):2327–2337. https://doi.org/10.1093/eurheartj/ehv253CrossRefPubMedPubMedCentral

22.

Dal Ferro M, Stolfo D, Altinier A et al (2017) Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart 103(21):1704–1710. https://doi.org/10.1136/heartjnl-2016-311017CrossRef

23.

Klauke B, Gaertner-Rommel A, Schulz U et al (2017) High proportion of genetic cases in patients with advanced cardiomyopathy including a novel homozygous Plakophilin 2‑gene mutation. PLoS ONE 12(12):e189489. https://doi.org/10.1371/journal.pone.0189489CrossRefPubMedPubMedCentral

24.

Tayal U, Newsome S, Buchan R et al (2017) Phenotype and clinical outcomes of Titin cardiomyopathy. J Am Coll Cardiol 70(18):2264–2274. https://doi.org/10.1016/j.jacc.2017.08.063CrossRefPubMedPubMedCentral

25.

Felkin LE, Walsh R, Ware JS et al (2016) Recovery of cardiac function in cardiomyopathy caused by Titin truncation. JAMA Cardiol 1(2):234–235. https://doi.org/10.1001/jamacardio.2016.0208CrossRefPubMedPubMedCentral

26.

Roberts AM, Ware JS, Herman DS et al (2015) Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med 7(270):270ra6. https://doi.org/10.1126/scitranslmed.3010134CrossRefPubMedPubMedCentral

27.

Tobita T, Nomura S, Fujita T et al (2018) Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep 8(1):1998. https://doi.org/10.1038/s41598-018-20114-9CrossRefPubMedPubMedCentral

28.

Janin A, N’Guyen K, Habib G et al (2017) Truncating mutations on myofibrillar myopathies causing genes as prevalent molecular explanations on patients with dilated cardiomyopathy. Clin Genet 92(6):616–623. https://doi.org/10.1111/cge.13043CrossRefPubMed

29.

Pugh TJ, Kelly MA, Gowrisankar S et al (2014) The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med 16(8):601–608. https://doi.org/10.1038/gim.2013.204CrossRefPubMed

30.

Siu BL, Niimura H, Osborne JA et al (1999) Familial dilated cardiomyopathy locus maps to chromosome 2q31. Circulation 99(8):1022–1026CrossRef

31.

Gerull B, Atherton J, Geupel A et al (2006) Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy. J Mol Med 84(6):478–483. https://doi.org/10.1007/s00109-006-0060-6CrossRefPubMed

32.

Gerull B, Gramlich M, Atherton J et al (2002) Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 30(2):201–204. https://doi.org/10.1038/ng815CrossRefPubMed

33.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med 6(6):e1000097. https://doi.org/10.1371/journal.pmed1000097CrossRefPubMedPubMedCentral

Titel: Prevalence of TTN mutations in patients with dilated cardiomyopathy
A meta-analysis
verfasst von: H.-J. Fang, MM
B.-P. Liu, MPH
Publikationsdatum: 17.06.2019
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe Sonderheft 1/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-019-4825-4

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Prevalence of TTN mutations in patients with dilated cardiomyopathy

A meta-analysis

Abstract

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2020

Aktuelles zur evidenzbasierten medikamentösen Herzinsuffizienztherapie

Predictive value of fibrinogen-to-albumin ratio in acute coronary syndrome

Pericardial complications and postcardiac injury syndrome after cardiovascular implantable electronic device placement

Deactivation of cardiovascular implantable electronic devices in patients nearing end of life

QTc interval prolongation during recovery from brief high-intensity intermittent exercise in obese adults

Erratum to: Stroke in patients with prosthetic valve endocarditis

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie